Latest Conference Articles

November 12th 2020, 5:30pm

November 12, 2020 - In an effort to further improve outcomes without sacrificing tolerability, the combination of cabozantinib with pembrolizumab is being evaluated in patients with advanced melanoma in a phase 1b/2 study.

November 10th 2020, 9:37pm

PER® New York Lung Cancer Symposium

November 10, 2020 - Nasser Hanna, MD, discusses immunotherapy and, although, it may be the right therapy for most patients with lung cancer expressing PD-L1 greater than or equal to 50%, for those who are at risk for cancer-related morbidity with early progressive disease, chemoimmunotherapy may be the more appropriate choice.

November 9th 2020, 10:57pm

PER® New York Lung Cancer Symposium

Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.

November 9th 2020, 10:19pm

PER® New York Lung Cancer Symposium

Although historically considered to be undruggable, the KRAS G12C mutation has since emerged as an actionable alteration in the field of non–small cell lung cancer.

November 9th 2020, 10:09pm

International Kidney Cancer Symposium

The coronavirus disease 2019 pandemic has led to delays in elective and potentially curative surgeries for patients with cT1b-cT2b renal cell carcinoma but research has indicated that surgical delays of up to and beyond 3 months did not result in an increased risk of pT3a upstaging or comprise overall survival.

November 9th 2020, 9:34pm

PER® New York Lung Cancer Symposium

Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.

November 9th 2020, 8:34pm

PER® New York Lung Cancer Symposium

The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.

November 8th 2020, 4:01pm

PER® Chemotherapy Foundation Symposium (CFS)

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

November 7th 2020, 10:12pm

PER® New York Lung Cancer Symposium

Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.

November 7th 2020, 9:45pm

International Kidney Cancer Symposium

A modified dosing schedule of frontline nivolumab (Opdivo) and ipilimumab (Yervoy) compared with the standard dose showed no differences in responses or safety in patients with advanced renal cell carcinoma, according to results of the CheckMate-920 trial.

November 7th 2020, 9:42pm

A 14-mg dose of lenvatinib showed similar safety to the standard 18-mg dose of the agent, when used in combination with everolimus in the second-line treatment of patients with advanced renal cell carcinoma, but noninferiority could not be confirmed.

November 7th 2020, 9:15pm

International Kidney Cancer Symposium

Recent research for effective therapies designed to target von Hippel-Lindau disease–associated renal cell carcinoma is pointing to a future with the paradigm that comprises immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors.

November 7th 2020, 8:38pm

International Kidney Cancer Symposium

Combination regimens comprised of immunotherapy and TKI inhibitors have yielded significant benefits in terms of overall survival and progression-free survival with acceptable safety in patients with renal cell carcinoma; however, the cost of these regimens may negate the impact of these advances.

November 7th 2020, 8:30pm

PER® New York Lung Cancer Symposium

Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.

November 7th 2020, 6:26pm

PER® New York Lung Cancer Symposium

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

November 7th 2020, 5:00pm

PER® New York Lung Cancer Symposium

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

November 7th 2020, 5:00pm

PER® New York Lung Cancer Symposium

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

November 7th 2020, 11:30am

International Kidney Cancer Symposium

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

November 7th 2020, 11:30am

International Kidney Cancer Symposium

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

November 6th 2020, 11:17pm

International Kidney Cancer Symposium

The combination of lenvatinib plus pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy.